Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications

Table 6

Cumulative total per-patient cost (in USD) of pharmacotherapy related to inflammatory bowel disease, by treatment group and duration of follow-up.

Treatment group	Month 3; Mean (SD)	Month 6; Mean (SD)	Month 9; Mean (SD)	Month 12; Mean (SD)
Oral 5-ASA ()	589 (424)	926 (699)	1,251 (1,089)	1,552 (1,418)
Mesalamine suppository ()	460 (330)	663 (607)	815 (829)	986 (1,095)
Mesalamine enema )	514 (369)	646 (596)	850 (929)	995 (1,172)

Oral 5-ASA: oral 5-aminosalicylate.